紅日藥業(300026.SZ):鹽酸沙格雷酯片國內首家獲批上市
格隆匯6月2日丨紅日藥業(300026.SZ)宣佈,公司於近日收到國家藥監局下發的關於鹽酸沙格雷酯片(100mg)的藥品註冊批件(批件號:2021S00511)。
鹽酸沙格雷酯片是選擇性5-羥色胺受體抑制劑的代表藥物之一,它的作用有使血小板黏附聚集以及釋放,改善側枝循環,抑制平滑肌增生抑制血管收縮。臨牀上應用於慢性動脈閉塞症所引起的潰瘍、疼痛等缺血性諸症狀的改善,及冠狀動脈粥樣硬化性心臟病、糖尿病、雷諾病等。
鹽酸沙格雷酯片目前國內僅有原研天津田邊製藥有限公司獲得批准上市,公司是該產品同品種國內首家獲批並且是第一個通過一致性評價的廠家。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.